Trajan Group Holdings Ltd (TRJ) AI Stock Analysis

• Market Cap: AU$112.12M
• Dividend Yield: N/A
• Average Volume (3M): 25.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: 7.38%
• EPS Growth: 82.39%
• Country: AU
• Employees: 600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 152,540,020
• 10 Day Avg. Volume: 35,402
• 30 Day Avg. Volume: 25,400
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.23
• Price Target Upside: 66.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 55 Neutral
• Price Target: AU$1.00 ▲(35.14% Upside)

The overall stock score is primarily influenced by financial performance challenges, including negative net income and cash flow issues. Technical analysis provides some positive signals with a short-term upward trend, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh heavily on the score.

Trajan Group Holdings Ltd Business Overview & Revenue Model

Company Description

Trajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company operates through two segments, Analytical Products and Life Science Solutions. It offers analytical products, including syringes, GC consumables, septas, caps, liners, gas filters, and tubing products; pathology solutions; and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance. In addition, it offers automation workflow solutions, micro sampling devices, and data analysis services. Trajan Group Holdings Limited was incorporated in 2011 and is headquartered in Ringwood, Australia.

How the Company Makes Money

Trajan Group Holdings Ltd generates revenue through the sale of its precision consumables and scientific instruments. The company's key revenue streams include direct sales to laboratories and research facilities, partnerships with scientific and healthcare organizations, and distribution agreements with global distributors. Trajan's growth is further supported by continuous innovation in product development and strategic acquisitions that expand its product offerings and market reach. The company also benefits from long-term relationships with clients in the health, environment, and food sectors, which demand consistent and high-quality analytical solutions.

Trajan Group Holdings Ltd Financial Statement Overview

Summary

Trajan Group Holdings Ltd is experiencing moderate revenue growth but is facing profitability challenges with negative net income. The balance sheet shows a stable equity position but is impacted by the negative return on equity. Cash flow management needs improvement, particularly in generating free cash flow. The company should focus on enhancing operational efficiency and profitability to strengthen its financial position.

Income Statement

Trajan Group Holdings Ltd has shown a modest revenue growth rate of 4.29% in the most recent year, indicating a positive trend. However, the company is currently experiencing negative net income, resulting in a negative net profit margin. The gross profit margin is relatively healthy, but the EBIT and EBITDA margins are low, suggesting challenges in operational efficiency and cost management.

Balance Sheet

The company's debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. However, the return on equity is negative due to the net loss, which is a concern. The equity ratio is stable, showing a solid foundation of equity relative to total assets.

Cash Flow

Free cash flow has decreased by 20.04%, which is a negative indicator. The operating cash flow is positive and covers net income, but the free cash flow to net income ratio is not favorable due to the net loss. The company needs to improve its cash flow generation to support operations and growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	159.62M	166.46M	155.02M	162.15M	107.57M	76.57M
Gross Profit	60.24M	63.47M	59.75M	22.93M	42.63M	28.48M
EBITDA	10.95M	8.14M	-20.36M	14.86M	5.14M	3.46M
Net Income	-28.48M	-4.46M	-25.33M	1.89M	1.70M	1.88M
Balance Sheet
Total Assets	199.03M	195.63M	188.00M	229.04M	206.78M	99.38M
Cash, Cash Equivalents and Short-Term Investments	10.44M	11.85M	11.24M	11.04M	13.16M	51.72M
Total Debt	55.94M	55.49M	56.16M	61.30M	66.18M	17.02M
Total Liabilities	93.36M	90.01M	85.15M	99.51M	90.27M	33.30M
Stockholders Equity	105.67M	105.62M	102.85M	129.53M	116.51M	66.08M
Cash Flow
Free Cash Flow	8.43M	6.74M	6.43M	998.00K	-1.28M	8.34M
Operating Cash Flow	11.95M	10.83M	9.47M	9.55M	2.13M	9.45M
Investing Cash Flow	-3.52M	-4.09M	-3.04M	-8.55M	-116.38M	402.00K
Financing Cash Flow	-9.99M	-5.64M	-6.40M	-3.36M	74.69M	36.81M

Trajan Group Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.84, and below the 200-day MA of 0.85, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 30.37 is Neutral, neither overbought nor oversold. The STOCH value of 24.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRJ.

Trajan Group Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	77 Outperform	103.31M	15.02	―	1.82%	0.65%	-9.90%
AHC	76 Outperform	136.78M	22.39	―	―	39.98%	-30.04%
TRJ	55 Neutral	AU$112.12M	―	-4.28%	―	7.38%	82.39%
CYC	42 Neutral	93.35M	-6.95	-30.89%	―	34.20%	-23.90%
SHG	40 Underperform	85.95M	-12.11	―	―	―	―
ALA	40 Underperform	110.13M	-13.53	―	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Trajan Group Holdings Ltd Corporate Events

Trajan Group Announces Board Changes Ahead of 2025 AGM

Trajan Group Holdings Limited announced that Sara Watts, Non-executive Director and Chair of the Audit and Risk Committee, will retire from the Board and not seek re-election at the 2025 Annual General Meeting. Her departure marks the end of her tenure since joining the Board in March 2021, just before the company’s IPO. Tiffiny Lewin will take over as Chair of the Audit and Risk Committee. This change in leadership may impact the company’s governance and strategic direction as it continues to focus on using science and medical technology to improve human wellbeing.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Ltd Releases Corporate Governance Statement

Trajan Group Holdings Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms that the company has adhered to the ASX Corporate Governance Council’s principles and recommendations, ensuring transparency and accountability in its management and oversight practices.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Ltd Advances in High Precision and Disruptive Technologies

Trajan Group Holdings Ltd is a leader in high precision products and services, offering a range of components, consumables, and capital equipment across various sectors. The company’s latest announcement highlights its commitment to innovation through disruptive technologies, aiming to enhance its market position and provide advanced solutions for stakeholders in biological, food, and environmental industries.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings to Release FY25 Results with Investor Engagement

Trajan Group Holdings Limited announced it will release its Full Year Results for the Financial Year ending June 30, 2025, on August 28, 2025. A live webcast and Q&A session will be hosted by the company’s CEO and CFO, allowing investors to engage and submit questions. This announcement is part of Trajan’s ongoing efforts to maintain transparency and engage with its stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Ltd Reports Record Revenue and Strong Financial Performance for FY25

Trajan Group Holdings Ltd announced a strong financial performance for FY25, with record revenue of $166.5M, surpassing its financial guidance despite a $3.9M loss from a discontinued biotech syringe revenue stream. The company experienced a 7.4% growth compared to FY24, outperforming the global scientific instruments sector. However, the Group nEBITDA fell short of expectations due to factors like unfavorable FX revaluation and delayed shipments. Trajan’s cash position improved, with cash and equivalents rising to $11.9M and net debt reduced to $29.6M, indicating a stronger financial footing. The company is optimistic about continued EBITDA and margin expansion in FY26, supported by its diversified portfolio and strong customer relationships.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.